Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
February 09, 2017 at 15:13 PM EST
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) dropped 2 percent Thursday on news of the FDA’s approval of Marathon ...